Jazz Pharmaceuticals plc

JAZZ

IE00B4Q5ZN47

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:38:26 17/07/2024 BST			5-day change	1st Jan Change
108.3 ^USD	+2.12%		+5.83%	-12.04%

07-10	Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer	CI
07-09	RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating	MT

Jazz Pharmaceuticals plc Provides Revenue Guidance for the Year 2021 and Provides Revenue Target for the Year 2025

January 10, 2022 at 12:30 pm

Jazz Pharmaceuticals plc provided revenue guidance for the year 2021 and provides revenue target for the year 2025. For the year 2021, the company expects revenue to be in the range of $3.02 billion to $3.1 billion.

For the year 2025, the company expects to generate $5 billion in revenue.

Latest news about Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer	07-10	CI
RBC Trims Price Target on Jazz Pharmaceuticals to $175 From $176, Keeps Outperform Rating	07-09	MT
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 3000E Growth Index	06-30	CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 1000 Growth Index	06-30	CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell Midcap Growth Index	06-30	CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 3000 Growth Index	06-30	CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index	06-30	CI
Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating	06-20	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	06-20	MT
Sector Update: Health Care	06-20	MT
Jazz Pharmaceuticals Says Phase 2b Trial for Suvecaltamide Misses Primary Endpoint -- Shares Slump Pre-Bell	06-20	MT
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study	06-20	RE
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor	06-20	CI
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM	06-12
Transcript : Jazz Pharmaceuticals plc Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 02:00 PM	06-06
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024	06-01	CI
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board	05-31	CI
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024	05-30	CI
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday	05-29	MT
Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer	05-29	MT
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application for Zanidatamab	05-29	CI
Transcript : Jazz Pharmaceuticals plc Presents at Bank of America Health Care Conference 2024, May-15-2024 10:00 AM	05-15
US reclassification could drive fresh research funding into pot sector	05-13	RE
Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing	05-07	MT

Chart Jazz Pharmaceuticals plc

Duration

Period

More charts

Company Profile

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Jazz Pharmaceuticals plc

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

106.1 USD

Average target price

178.4 USD

Spread / Average Target

+68.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JAZZ PHARMACEUTICALS PLC	-12.04%	6.69B
ELI LILLY AND COMPANY	+56.15%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.04%	363B
MERCK & CO., INC.	+15.39%	318B
ABBVIE INC.	+12.98%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.31%	179B
PFIZER, INC.	+4.03%	167B

Other Pharmaceuticals